Bayer AG (NASDAQ:BAYRY)‘s stock had its “outperform” rating reaffirmed by investment analysts at Sanford C. Bernstein in a note issued to investors on Friday.
Other equities analysts have also issued research reports about the stock. Jefferies Group LLC raised shares of Bayer AG from a “hold” rating to a “buy” rating in a report on Monday, December 19th. Zacks Investment Research lowered shares of Bayer AG from a “buy” rating to a “hold” rating in a report on Monday, November 21st. Finally, J P Morgan Chase & Co raised shares of Bayer AG from a “neutral” rating to an “overweight” rating in a report on Wednesday, January 4th.
Shares of Bayer AG (NASDAQ:BAYRY) traded down 0.57% during trading on Friday, reaching $110.74. 49,717 shares of the company were exchanged. Bayer AG has a 52-week low of $91.53 and a 52-week high of $125.20. The stock’s 50-day moving average is $110.73 and its 200-day moving average is $104.05. The firm has a market cap of $91.58 billion and a price-to-earnings ratio of 18.30.
About Bayer AG
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures.
